<DOC>
	<DOCNO>NCT00528567</DOCNO>
	<brief_summary>The main objective trial compare Invasive Disease-Free Survival ( IDFS ) patient randomise treatment adjuvant chemotherapy alone adjuvant chemotherapy 1 year bevacizumab . The secondary objective trial : - compare Overall Survival ( OS ) , Breast Cancer-Free Interval ( BCFI ) , Disease- Free Survival ( DFS ) Distant Disease-Free Survival ( DDFS ) patient randomise treatment adjuvant chemotherapy alone adjuvant chemotherapy combination 1 year bevacizumab - evaluate safety tolerability bevacizumab An exploratory sub-study ( report ) identify biomarkers ( tumour serum ) predictive toxicity level benefit addition bevacizumab standard adjuvant systemic treatment .</brief_summary>
	<brief_title>BEATRICE Study : A Study Bevacizumab ( Avastin ) Adjuvant Therapy Triple Negative Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>adult patient , &gt; =18 year age ; operable primary invasive breast cancer ; complete definitive locoregional surgery ; primary tumor centrally confirm triple negative . locally advanced breast cancer ; previous breast cancer history ; clinically significant cardiovascular disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>